NCT07066657

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 405 (estimated)
• Sponsor: ArriVent BioPharma, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

Conditions

• Locally Advanced or Metastatic Solid Tumors
• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	MRG007	MRG007 will be administrated as specified in the protocol.

Timeline

• Start date: 2025-07-25
• Primary completion: 2029-05-01
• Completion: 2030-12-01
• First posted: 2025-07-15
• Last updated: 2026-02-17

Locations

15 sites across 2 countries: United States, China

Regulatory

• FDA-regulated drug study